PHILADELPHIA, PA — HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced the launch of HealthVerity Audience Manager. This disruptive solution provides media agencies and life sciences organizations with a truly self-directed analytics environment that enables previously unattainable insights regarding patient behavior in combination with social determinants of health (SDOH), all in a privacy protected, HIPAA-compliant manner. Audience Manager is ideally suited to synchronize healthcare and SDOH data with ever-more sophisticated cohort modeling to precisely define audience segments for awareness campaigns, therapeutic studies and support programs.

Complex data privacy laws and limited analytics tools have historically made it challenging for media agencies and the life sciences industry to implement patient-centric engagement strategies. As therapies have become increasingly more personalized, it is more important than ever to ensure that the right patients receive the right medications in combination with any required support. Audience Manager is the only solution in the industry to empower media agencies and pharmaceutical manufacturers to synchronize proprietary enterprise data with the patient-centric RWD and SDOH data of their choice from the nation’s largest healthcare and consumer data ecosystem in a fully HIPAA-compliant manner. Organizations can leverage this self-directed analytics environment to build comprehensive views of patient journeys by contextualizing patient diagnoses, procedures and therapies with patient-centric social determinants of health, demographics and behaviors. This approach firmly places the power of discovery in the hands of organizations and provides a clear path to design approaches that reach the right patients in the right channels with the right messaging at the right time.

“Audience Manager flips the model on current industry standards that offer only pre-defined or ‘black box’ audience segments,” explained Ben Walker, general manager, media and consumer data at HealthVerity. “Instead, we empower media agencies and life sciences organizations to conduct their own analyses with their data in combination with healthcare and consumer data, all synchronized to unlock previously unattainable outcomes. This approach enables organizations to iterate approaches far more quickly and more accurately instead of hoping that ‘black box’ models are aligned with their outreach objectives.”

HealthVerity Audience Manager can be integrated with HealthVerity Media Measurement, a closed loop marketing solution that synchronizes digital media ad and television exposure data with pharmacy and medical transactions from patients of interest to assess campaign performance, understand the impact of targeting efforts and optimize campaigns in real time, all in a privacy-protected and HIPAA-compliant manner.

“HealthVerity Audience Manager will be a gamechanger for us,” explained Brandon King, SVP activation analytics with Fingerpaint, a full-service healthcare marketing company. “It will allow us to provide our clients with insights that were previously unattainable due to complex HIPAA regulations and data management issues industrywide. With our partnership with HealthVerity, we will be able to integrate Audience Manager with Elevalt, our omnichannel orchestration engine, to not only meet all of our clients’ needs to optimize their campaigns, but also provide activation-ready insights.”

Ready to learn more? Watch our webinar, Break out of the black box and discover how you can break free of black box solutions to gain a deeper understanding of patient behavior.

PHILADELPHIA, PA — HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced the launch of the HealthVerity Chronic Kidney Disease (CKD) Masterset, an expertly curated dataset developed in collaboration with Aetion that synchronizes lab results, commercial, Medicare and Medicaid claims, and electronic medical records (EMRs) from the nation’s largest healthcare and consumer data ecosystem. An addition to our growing suite of HealthVerity Mastersets, including the Provider Diversity Index 2023 edition and the Maternal Outcomes Masterset, the CKD Masterset compiles all CKD-relevant clinical attributes into one comprehensive, research-ready masterset, accelerating research by saving valuable time and resources.

Currently, there is no cure for CKD, a progressive condition that impacts one in seven adults in the U.S., or approximately 37 million people, 90% of whom do not even know they have the disease until it has already advanced to a late stage.¹ To slow progression of CKD, which is a leading cause of death in the U.S., researchers need to understand the patient journey.²

The CKD Masterset, consisting of approximately 7 million patients with a confirmed medical diagnosis or lab result, was developed to provide speed to the novel insights that researchers need to understand disease progression, the impact of existing interventions, and patient outcomes over time and in real time. HealthVerity experts standardize and deduplicate the data, ensuring all of the most relevant CKD data points are included without additional noise from RWD, providing a more concise, easy-to-use masterset.

“CKD is complicated by several comorbid conditions, such as diabetes, hypertension and heart disease,” explained Reyna Klesh, vice president, data products and innovation at HealthVerity. “By integrating the revealing aspects of the journey for patients at every stage of CKD, in a HIPAA-compliant format, we help researchers better understand disease progression to develop effective treatments for the millions of people affected by the disease.”

The closed claims data provides a longitudinal view of the patient journey and the EMR data provides valuable clinical observations, including body mass index, height, weight, smoking status, diastolic and systolic blood pressure, ejection fraction, and alcohol usage. These diagnostic measures allow users to observe changes in vital status and understand risk factors for worsening disease over time. The lab data provides the critical results for understanding what stage of CKD the patient is in, determining kidney function and the extent of damage to the kidneys, including estimated glomerular filtration rates (eGRF), urine albumin-creatinine ratio (uACR), albumin and creatinine, as well as HbA1c levels. Any duplicative results from these data sources are removed to deliver the most concise results to the user. Race, ethnicity and mortality data is also provided for the most comprehensive view of the CKD patient journey.

HealthVerity will continue to add to their Masterset Series, providing researchers speed to insights through expertly curated datasets that profile some of the most important diseases.

Attending ICPE 2023? Book your meeting with the HealthVerity team at booth #402 in Halifax, Nova Scotia, August 23-27, 2023.

About HealthVerity

HealthVerity synchronizes transformational technologies with the nation’s largest healthcare and consumer data ecosystem to power previously unattainable outcomes and fundamentally advance the science. We offer a comprehensive, yet flexible approach, based on the foundational elements of Identity, Privacy, Governance and Exchange (IPGE), that synchronizes unparalleled Identity management with built-in Privacy compliance and Governance, providing the ability to discover and Exchange a near limitless combination of data at a record pace. Together with our partners in life sciences, government and insurance, we are Synchronizing the Science. To learn more about HealthVerity, visit healthverity.com.

HealthVerity Contact

Colleen Stoker
614-738-0592
cstoker@healthverity.com

Sources

¹ National Institute of Diabetes and Digestive and Kidney Diseases. National Kidney Month 2023.
https://www.niddk.nih.gov/health-information/community-health-outreach/national-kidney-month

² Centers for Disease Control and Prevention. Chronic Kidney Disease Basics.
https://www.cdc.gov/kidneydisease/basics.html

PHILADELPHIA, PA — HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced the release of the Provider Diversity Index (PDI) 2023 edition with breakthrough enhancements that help pharmaceutical manufacturers to prioritize physicians who are treating patients more reflective of the populations impacted by the conditions being studied.

First introduced in 2020, this nationally-syndicated report synchronizes medical, pharmacy and social determinants of health data from the nation’s largest data ecosystem to calculate the racial diversity of patients for over 1 million physician practices, all in a HIPAA-compliant manner. The HealthVerity PDI is being actively used by clients to identify clinical trial site investigators and to more effectively characterize and recruit patient populations that better reflect the diversity mix of diagnosed patients. New enhancements to the HealthVerity PDI for 2023, such as age range, gender, income range, payer type (commercial, Medicare or Medicaid) and diagnosis further the mission of pharmaceutical manufacturers and CROs in achieving their diversity goals.

Alzheimer’s is an example of a condition that disproportionately affects minorities. According to the Alzheimer’s Association, 19% of Black/African American and 14% of Hispanic/Latino adults age 65 and older have Alzheimer’s, compared to 10% of White/Caucasian seniors.¹ In contrast, participants in a 2020 clinical trial for an Alzheimer’s medication were 86% White/Caucasian.² The latest HealthVerity PDI leverages diagnosis in a HIPAA-compliant manner to highlight physicians treating broader cohorts of minority patients whose recruitment could yield more effective clinical trial results.

Age is another important consideration for Alzheimer’s research. The Alzheimer’s Association reported that clinical trial sites for memory impairment drugs do not cohesively align with areas that have larger populations of individuals 60 years of age and older, causing strain on sites in areas of higher density senior populations while leaving other individuals having to travel 50 miles to get to a clinical trial site. This has led to lower performance and delayed timelines.³ With the enhancements to the HealthVerity PDI, researchers can discover physician practices that have representative patient populations for race, age and diagnosis to solve these recruitment challenges.

According to the 2020 U.S. Census, 57.8% of the population is White/Caucasian, 12.1% is Black/African American and 18.7% of the population is Hispanic/Latino. The FDA’s Center for Drug Evaluation and Research reported; however, that 75% of participants in 2020 clinical trials were White/Caucasian, only 8% were Black/African American and 11% were Hispanic/Latino, demonstrating the need for greater equity in clinical trials.²

The U.S. Food and Drug Administration (FDA) has placed a high importance on increasing equity in clinical trials, with Commissioner Robert M. Califf, M.D. stating in a release that “…ensuring meaningful representation of racial and ethnic minorities in clinical trials is fundamental to public health… [and] greater diversity will be a key focus of the agency to facilitate better treatments and better ways to fight diseases that disproportionately impact diverse communities.”⁴

“These statistics demonstrate how critical it is that researchers be able to work on clinical trials with physicians who have better access to patient populations representative of their particular study,” said Andrew Kress, CEO of HealthVerity. “We are proud to have the advanced technologies and privacy techniques to enable our clients to practice better medicine through diversity.”

About HealthVerity

HealthVerity synchronizes transformational technologies with the nation’s largest healthcare and consumer data ecosystem to power previously unattainable outcomes and fundamentally advance the science. We offer a comprehensive, yet flexible approach, based on the foundational elements of Identity, Privacy, Governance and Exchange (IPGE), that synchronizes unparalleled Identity management with built-in Privacy compliance and Governance, providing the ability to discover and Exchange a near limitless combination of data at a record pace. Together with our partners in life sciences, government and insurance, we are Synchronizing the Science. To learn more about HealthVerity, visit healthverity.com.

HealthVerity Contact

Colleen Stoker
614-738-0592
cstoker@healthverity.com

Sources

¹ Alzheimer’s Association. 2023 Alzheimer’s Disease Facts and Figures.
https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf

² FDA (2021). 2020 Drug Trials Snapshots Summary Report.
https://www.fda.gov/media/145718/download

³ Stanton, S.; Dwyer, J.; Ward, N.; Vradenburg, G.; Taylor, J. (2020). Are U.S. clinical trial sites in the right places to meet the demand for the population density of those over 60? Alzheimer’s & Dementia, vol. 16, issue 10, December 7, 2020.

⁴ FDA (2022). FDA Takes Important Steps to Increase Racial and Ethnic Diversity in Clinical Trials.
hhttps://www.prnewswire.com/news-releases/fda-takes-important-steps-to-increase-racial-and-ethnic-diversity-in-clinical-trials-301524987.html

Today marks an historic day for HealthVerity as we launch our most ambitious effort yet to capture the imagination of our industry. As you may know, HealthVerity first disrupted the market by introducing software for identity management that was 10x more accurate than legacy alternatives. Our investments in privacy and governance technologies further led us to being the first in the industry to launch a marketplace that has now become the nation’s largest healthcare and consumer data ecosystem. Success has been hard fought, but customers have always appreciated our unique IPGE approach, based on the foundational elements of Identity, Privacy, Governance and Exchange as well as the strength of the data in HealthVerity Marketplace that supports their research objectives.

The market, however, never stands still and others have borrowed heavily from our marketing positioning, even introducing marketplaces of their own. While others make claims about how they can link data, we know that the token is broken and that no one can match our technological advantages in unlocking value from real-world data. HealthVerity recognizes that the time is right to move the market forward again and to establish a new standard for what it means to delight pharmaceutical, government, insurance and analytics clients.

It’s time to Synchronize the Science and empower customers to benefit from HealthVerity’s unique ability to synchronize transformational technologies with the nation’s largest healthcare data ecosystem to power previously unattainable outcomes and to advance the science. We are the only company that has the ideal combination of mission critical software and data expertise to enable clients to get more out of the hundreds of millions of comprehensive patient journeys that we can deliver in a privacy-protected, HIPAA-compliant manner.

It’s also time to prove to our customers that Synced beats Linked. As such, we are pleased to introduce HealthVerity FLOW, our pharma-class SaaS solution that synchronizes unparalleled identity management with built-in privacy and data governance, allowing customers to discover and exchange a near limitless combination of healthcare and consumer data at a record pace. HealthVerity FLOW is designed to open new pathways to progress by integrating all of our core capabilities in a modular software architecture that is ideal for broadening data capture and performance for registries, clinical trials and commercial endeavors. Even more importantly, HealthVerity FLOW enables clients to comply with regulatory frameworks and to compliantly study comprehensive patient journeys throughout the therapeutic lifecycle. We are already seeing adoption by top pharma during pre-launch and believe that data-driven customers will quickly recognize the superiority of synchronization.

On behalf of all of HealthVerity, we are so excited by today’s announcement. We join our customers in agreeing that innovation is best achieved when you Sync Big. This is a powerful notion and one that will drive everything we will do in the years ahead.

PHILADELPHIA, PA — HealthVerity, the leader in synchronizing transformational technologies and real-world data (RWD) to advance the science, today announced the launch of HealthVerity FLOW, a pharma-class Software-as-a-Service solution that enables pharmaceutical manufacturers to integrate extensive RWD capabilities with patient-centric compliance across the full spectrum of registries, clinical trials and commercial activities. HealthVerity FLOW is the ideal choice for data-driven companies seeking to unify and accelerate the process for building more comprehensive patient journeys in a highly accurate, privacy protecting manner while also ensuring that data rights and data management are governed uniformly across the enterprise.

Pharmaceutical companies have traditionally invested billions of dollars in registries and clinical trials to collect first-party data from patients on a blinded basis. This technique insulated sponsors from more complex data compliance issues, but ultimately limited the speed and quality of patient analytics that could be conducted in advance of initial regulatory submissions or applications for new indications. Advances in data science, however, combined with the breadth of HIPAA-compliant data now available, have prompted a movement by market leaders to seek approval from Institutional Review Boards (IRBs) to benefit from these trends. This is further supported by regulatory agencies that are increasingly more accepting of RWD, with appropriate provenance, as an important component in regulatory filings. Despite the momentum, companies are struggling with the burdens of effectively managing patient permissions, discovering and sourcing third-party patient data, governing the exchange of data between sources and researchers, and managing the complex workflows across numerous registries, clinical trials and commercial initiatives.

HealthVerity FLOW is already experiencing rapid adoption among top 20 pharma organizations due to a modular platform that synchronizes leading technologies for identity, privacy and governance with the nation’s largest healthcare and consumer data ecosystem. HealthVerity FLOW enables customers to move beyond legacy tokenization and to establish a unique, but persistent source of truth for patients enrolled in registries and studies. By managing identity with 10x greater accuracy than legacy technologies, HealthVerity FLOW can more effectively orchestrate all types of RWD collection and exchange, all within a HIPAA and 21 CFR 11-compliant environment that delivers regulatory-ready data in real-time across the most critical use cases. The flexibility of the HealthVerity FLOW infrastructure makes it ideal to power patient-centric efforts through all phases of therapeutic development while offering a RWD-driven alternative for patients lost to follow up, safety surveillance and pursuit of real-world evidence for new indications.

”HealthVerity FLOW is remarkable in its ability to simplify and streamline the capture, compliance and study of comprehensive patient journeys before, during and after clinical trials,” said Andrew Kress, CEO of HealthVerity. “The promise of broad-scale adoption of a solution that leverages advanced technologies for enriching first-party clinical data with RWD should enhance the quality of regulatory submissions, reduce time to approval and significantly improve patient outcomes in the future.”

HealthVerity is hosting a webinar introducing HealthVerity FLOW on May 23 at 12:00 p.m. Interested parties may register here with replays available on May 24 in our Resource Library.

About HealthVerity

HealthVerity synchronizes transformational technologies with the nation’s largest healthcare and consumer data ecosystem to power previously unattainable outcomes and fundamentally advance the science. We offer a comprehensive, yet flexible approach, based on the foundational elements of Identity, Privacy, Governance and Exchange (IPGE), that synchronizes unparalleled Identity management with built-in Privacy compliance and Governance, providing the ability to discover and Exchange a near limitless combination of data at a record pace. Together with our partners in life sciences, government and insurance, we are Synchronizing the Science. To learn more about HealthVerity, visit healthverity.com.

HealthVerity Contact

Colleen Stoker
614-738-0592
cstoker@healthverity.com

BERKELY HEIGHTS, NJ & PHILADELPHIA, PA — Axtria, Inc., a global leader of award-winning cloud software and data analytics, and HealthVerity, the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, today announced a partnership to provide life sciences organizations with the data, analytics and infrastructure required to enable comprehensive and privacy-compliant views of patient journeys across all engagement channels.

“This partnership combines our best-in-class patient identity resolution technology, consent management solutions and real-world data ecosystem with Axtria’s leading analytics capabilities to fundamentally change how life sciences organizations interact with patients,” said HealthVerity CEO Andrew Kress. “We are excited to offer unprecedented insight into the patient journey and unlock significantly more bandwidth for our clients to innovate.”

The HealthVerity IPGE platform is an integrated technology and real-world data (RWD) infrastructure that allows disparate data to be accurately resolved to unique privacy-protected identities, then connected in a HIPAA-compliant manner, enabling interoperability with the nation’s largest healthcare and consumer data ecosystem. This partnership allows the power of the HealthVerity data ecosystem to be applied to Axtria’s analytics products and services to solve real-world problems, driving breakthroughs in artificial intelligence (AI) and machine learning (ML).

“For life sciences companies, successfully competing in today’s environment requires a deep understanding of the patient journey and their ever-changing needs. This is only possible when the best data is combined with the best analytics and seamless delivery of insights in real-time,” said Axtria CEO Jaswinder Chadha. “Axtria has always been at the forefront of clinical and commercial innovation, and this partnership is another step in that direction, so our customers are equipped to win in a highly competitive landscape where winners will be decided based on how well they understand and solve patient needs.”

Through this partnership, Axtria and HealthVerity will offer best-in-class solutions to help drive clinical and commercial impact. Specifically, they will enable companies to manage patient identities and consent and, as appropriate, capture and match patient-level data across engagement channels, such as advertising, specialty pharmacies and hubs, patient support programs and other digital applications—all in a HIPAA-compliant manner. On top of this infrastructure, they will apply advanced analytics for applications such as trigger programs that inform next-best actions and closed-loop media attribution that links marketing campaigns to actual patient behavior.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

About Axtria

Axtria is a global provider of award-winning cloud software and data analytics to the life sciences industry. Axtria’s solutions are used to digitally transform the entire product commercialization process, supporting RWE/HEOR, medical affairs, pricing and market access, product launch, and post-launch, and marketing and sales operations to drive growth and improve healthcare outcomes for patients. Our focus is on delivering solutions that help pharmaceutical, medical device, and diagnostics companies complete the journey from data to insights to action and get superior returns from their investments. For more information, visit www.axtria.com.

HealthVerity Contact

Colleen Stoker
614-738-0592
cstoker@healthverity.com

Axtria Contact

Jennifer Salah
877-929-8742
connect@axtria.com

PHILADELPHIA, PA — HealthVerity, the leader in Identity, Privacy, Governance and Exchange (IPGE) for real-world data (RWD), announced that it entered into a feasibility study with the Food and Drug Administration’s (FDA’s) Sentinel Innovation Center, a national program led by Mass General Brigham and Harvard Pilgrim Health Care Institute that uses electronic health data for over 100 million people to monitor the safety of FDA-regulated drugs and other medical products.

Launched in 2008, the Sentinel Initiative has continued to grow and evolve, transforming the way researchers monitor the safety of FDA-regulated products and becoming the largest curated database in the world dedicated to medical product safety. In 2019, the Innovation Center was created as part of the Sentinel Initiative to explore methods for incorporating linked medical claims and electronic health record (EHR) data into the Sentinel System for 10 million lives within five years. EHR data provides more clinical detail than insurance claims and is expected to address current gaps in the Sentinel System’s capabilities.

HealthVerity was selected to participate in this undertaking. During the 14-month project, select EHR data from the vast HealthVerity data ecosystem, consisting of over 75 unique data sources representing more than 330 million de-identified patients, will be converted into the Sentinel Common Data Model, and evaluated to ensure the data is fit for purpose.

“HealthVerity is honored to be a part of this groundbreaking initiative supporting the FDA’s goal to incorporate EHR data into the Sentinel System,” said Andrew Kress, CEO, and co-founder of HealthVerity. “We look forward to working with the Sentinel team during this project and identifying important future collaborations.”

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

CHICAGO, IL and PHILADELPHIA, PA — Veradigm^®, a leading provider of healthcare data and technology solutions (NASDAQ: MDRX), and HealthVerity^®, a leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data, today announced a collaboration that will advance real-world research and improve patient care for those with cardiovascular disease and diabetes. The collaboration makes Veradigm’s data from their Cardiovascular and Metabolic Registries fully interoperable with de-identified patient data from HealthVerity Marketplace, the nation’s largest healthcare and consumer data ecosystem.

The HealthVerity IPGE platform is an integrated technology and real-world data (RWD) infrastructure that allows disparate data to be accurately resolved to unique privacy-protected identities, then linked in a HIPAA-compliant manner and exchanged for a myriad of use cases. By connecting Veradigm’s Cardiology and Metabolic registries with broad scale healthcare and consumer data from HealthVerity, the collaboration provides clinical researchers with unprecedented access to regulatory-quality, HIPAA-compliant and research-ready data to advance analytics and treatments for these prevalent conditions.

The Veradigm Cardiology Registry is the largest U.S. outpatient cardiovascular quality improvement registry, with 102+ million records, representing 18.9+ million unique patient lives, 13,000 providers and 4,000 office locations. The registry captures data on coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), hypertension (HTN) and peripheral arterial disease (PAD). It follows cardiac patients across their journey, tracking key measures, including patient demographics, plan of care, cardiac events and comorbidities, exams, procedures, lab values, related medications, and more.

The Veradigm Metabolic Registry is the first clinical ambulatory registry aimed at tracking and improving the quality of prediabetes, diabetes, and cardiometabolic care across the primary and specialty care continuum. The registry has 79+ million records, representing 13.5+ million unique patient lives, 11,100 providers, and 3,400 office locations. Key measures captured include patient demographics, A1c control, nephropathy, blood cholesterol, hypertension eye exam, foot exam, antiplatelet therapy and more. Additionally, Veradigm’s electronic health record (EHR) data from the most recent five years is incorporated, representing over 176 million patients with clinical activity, as well as Veradigm medical claims and remittance data for 300 million medical claims captured in a rolling two-year period.

“Veradigm provides life science researchers scalable access to real-world clinical data via our direct connection with the point-of-care,” said Stuart Green, Senior Vice President and General Manager, Veradigm. “With Veradigm’s Registry and EHR data on the HealthVerity platform, we are extending the reach of the Veradigm Network to further support improvements in patient care at scale.”

The collaboration between Veradigm and HealthVerity leverages the industry’s most accurate patient matching and identity resolution technology, a key component of the HealthVerity IPGE Platform, which will allow researchers to discover more comprehensive longitudinal patient journeys without the patient fragmentation inherent in more traditional patient tokenization solutions.

“Diabetes is a top driver of healthcare spend and, as we enter Heart Health Month, we are reminded of the need for comprehensive treatments for heart disease, a leading cause of death in the United States,” said Andrew Kress, CEO of HealthVerity. “This collaboration will enable far greater contextualization of important registry data and will provide a more holistic view of these patients’ journeys. Life Sciences organizations and clinical researchers can now obtain comprehensive patient-level data in a privacy-protected manner that offers real-world insight into the patient to ultimately improve care for these ubiquitous conditions.”

About Veradigm

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully. For more information on Veradigm, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Veradigm
Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@veradigm.com

HealthVerity
Colleen Stoker
cstoker@healthverity.com

NEW YORK, NY — Lumanity and HealthVerity today announced a strategic partnership that will enable life sciences companies to derive better outcomes from the HealthVerity IPGE platform, including the nation’s largest, fully-interoperable healthcare and consumer data ecosystem, in combination with Lumanity’s world-class data and real-world evidence (RWE) generation expertise. The partnership creates tremendous value for clients seeking to leverage Lumanity’s unique ability to identify the optimal, research-ready real-world data (RWD) to support real-world research, as well as its strengths in global health economics and outcomes research (HEOR), safety, and data analytics.

“We are thrilled to partner with HealthVerity as part of the launch of our global RWE practice,” said Gema Parlange, Chief Commercial and Development Officer and the Global Practice Lead for RWE at Lumanity. “We are very impressed with the depth and breadth of the HealthVerity IPGE platform, including its highly accurate patient identity resolution technology and broad ecosystem of data partners, and are excited about the possibilities of bringing multi-source, cohort-specificity together with our deep domain expertise in HEOR and Value Demonstration. We look forward to working together to provide innovative new solutions for our clients and partners.”

The HealthVerity IPGE platform is an integrated technology and RWD infrastructure based on four foundational elements, Identity, Privacy, Governance, and Exchange, that allow disparate data to be accurately resolved to unique but persistent identities, linked, and exchanged in a privacy-protected manner for a myriad of use cases. The HealthVerity RWD ecosystem supports a comprehensive array of customer use cases that leverage the convergence of medical claims data, lab data and results, pharmacy data, EMR data, hospital chargemaster data, and social determinants of health data.

“This partnership combines our 10x accuracy advantage in patient identity resolution, access to novel data assets, and Lumanity’s deep domain expertise in HEOR, value demonstration, patient-reported outcomes, and media strategy,” said Sandy Leonard, Senior Vice President of Partnerships and RWD Solutions at HealthVerity. “We believe this is a powerful combination to help our customers build more complete and accurate patient journeys to support their most pressing research and analytics projects.”

Lumanity was formed by bringing together the expertise and capabilities of several exceptional organizations, including Cello Health, BresMed, Guidemark Health, Cyan Health, Zipher Medical Affairs, Innovative Edge, Endpoint Outcomes, and Clarion. The partnership with HealthVerity comes on the heels of launching Lumanity’s Real World Evidence global practice, and further enhances Lumanity’s unique and diverse collection of deeply experienced industry pioneers, data luminaries, subject matter experts, and proven problem solvers with advanced clinical, scientific, and real-world data capabilities.

About Lumanity

Lumanity applies incisive thinking and decisive action to cut through complex situations and deliver transformative outcomes to accelerate and optimize access to medical advances. By transforming data and information into real-world insights and evidence, Lumanity powers successful commercialization and empowers patients, providers, payers, and regulators to take timely and decisive action. With offices in North America, the United Kingdom, Europe, and Asia, and work conducted in over 50 countries, its 1,300+ experts work with nearly all the top pharmaceutical and more than 100 biotech companies around the world. Turning aspiration into reality, Lumanity supports over 50 payer submissions across 20+ countries, launch readiness and commercialization of 80 brands and new indications, and numerous award-winning product campaigns every year. For more information, please visit lumanity.com and connect with Lumanity on Twitter and LinkedIn

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.

Contact

Lumanity
Peter Marangos
+1 702 776 0985 / peter.marangos@lumanity.com

HealthVerity
Colleen Stoker
cstoker@healthverity.com